<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - OXYTOCIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>OXYTOCIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Induction of labour for medical reasons</span>,
                <span class="indication">Stimulation of labour in hypotonic uterine inertia</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 0.001&#8211;0.004 unit/minute, not to be started for at least 6 hours after administration of vaginal prostaglandin, dose increased at intervals of at least 30 minutes until a maximum of 3&#8211;4 contractions occur every 10 minutes (0.01 units/minute is often adequate) up to max. 0.02 units/minute, if regular contractions not established after a total 5 units, stop induction attempt (may be repeated next day starting again at 0.001&#8211;0.004 units/minute).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Caesarean section</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 units immediately after delivery.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of postpartum haemorrhage after delivery of placenta</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 units, if infusion previously used for induction or enhancement of labour, increase rate during third stage and for next few hours.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                10 units, can be used instead of oxytocin with ergometrine (Syntometrine ).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of postpartum haemorrhage</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 units, repeated if necessary.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of severe cases of postpartum haemorrhage (following intravenous injection)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                40 units, given in 500 mL infusion fluid given at a rate sufficient to control uterine atony.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Incomplete, inevitable, or missed miscarriage</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5 units, followed by (by intravenous infusion) 0.02&#8211;0.04 unit/minute if required, the rate of infusion can be faster if necessary.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>






      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Any condition where spontaneous labour inadvisable</li>
            <li>any condition where vaginal delivery inadvisable</li>
            <li>avoid intravenous injection during labour</li>
            <li>avoid prolonged administration in oxytocin-resistant uterine inertia</li>
            <li>avoid rapid intravenous injection (may transiently reduce blood pressure)</li>
            <li>fetal distress (discontinue immediately if this occurs)</li>
            <li>hypertonic uterine contractions (discontinue immediately if this occurs)</li>
            <li>severe cardiovascular disease</li>
            <li>severe pre-eclamptic toxaemia</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Arrhythmia, headache, nausea, vomiting,
              </p>
              <p>
                <strong>rare:</strong> Anaphylactoid reactions (with dyspnoea, hypotension, or shock), disseminated intravascular coagulation, hyponatraemia associated with high doses with large infusion volumes of electrolyte-free fluid, rash, uterine hyperstimulation (usually with excessive doses&#8212;may cause fetal distress, asphyxia, and death, or may lead to hypertonicity, tetanic contractions, soft-tissue damage or uterine rupture), uterine spasm (may occur at low doses), water intoxication associated with high doses with large infusion volumes of electrolyte-free fluid,
              </p>
        
        
            <section class="advice">
              <p>Avoid rapid intravenous injection (may transiently reduce blood pressure).</p>
            </section>
        
            <section class="overdosageInformation">
              <p>Placental abruption and amniotic fluid embolism reported on overdose.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>intravenous infusion</i> (<i>Syntocinon</i>
            <sup>
            <tm tmtype="reg"/>
            </sup>), give continuously in Glucose 5% <i>or</i> Sodium chloride 0.9%. Preferably given <i>via</i> a variable-speed infusion pump in a concentration appropriate to the pump; if given by drip infusion for <i>induction</i> or <i>enhancement of labour</i>, dilute 5&#8239;units in 500&#8239;mL infusion fluid or for higher doses, 10&#8239;units in 500&#8239;mL; for <i>treatment of postpartum uterine haemorrhage</i> dilute 40&#8239;units in 500&#8239;mL; if high doses given for prolonged period (e.g. for inevitable or missed abortion or for postpartum haemorrhage), use low volume of an electrolyte-containing infusion fluid (not Glucose 5%) given at higher concentration than for induction or enhancement of labour; close attention to patient's fluid and electrolyte status essential.</p>
            </section>
      </section>



      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <p>Prolonged intravenous administration at high doses with large volume of fluid (which is possible in inevitable or missed miscarriage or postpartum haemorrhage) may cause water intoxication with hyponatraemia. To avoid: use electrolyte-containing diluent (i.e. not glucose), increase oxytocin concentration to reduce fluid, restrict fluid intake by mouth; monitor fluid and electrolytes.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Avoid large infusion volumes and restrict fluid intake by mouth (risk of hyponatraemia and water-intoxication)
          </li>
          <li>
            enhancement of labour&#8212;presence of borderline cephalopelvic disproportion (avoid if significant)
          </li>
          <li>
            history of lower-uterine segment caesarean section
          </li>
          <li>
            induction of labour&#8212;presence of borderline cephalopelvic disproportion (avoid if significant)
          </li>
          <li>
            mild pregnancy-induced cardiac disease
          </li>
          <li>
            mild pregnancy-induced hypertension
          </li>
          <li>
            moderate pregnancy-induced cardiac disease
          </li>
          <li>
            moderate pregnancy-induced hypertension
          </li>
          <li>
            risk factors for disseminated intravascular coagulation
          </li>
          <li>
            secondary uterine inertia
          </li>
          <li>
            women over 35 years
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Careful monitoring of fetal heart rate and uterine motility essential for dose titration.</p><p>Monitor for disseminated intravascular coagulation after parturition.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use</h3>
              <p>Oxytocin doses in the BNF may differ from those in the product literature.</p><p>Intramuscular injection.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of OXYTOCIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for infusion,
            infusion,

            <div id="PHP74678"><a href="../medicinalForm/PHP74678.html" data-target="#PHP74678" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
